- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.04. | REVELATION BIOSCIENCES, INC. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 06.04. | Revelation Biosciences forms advisory board for AKI trial | 3 | Investing.com | ||
| 06.04. | Revelation Biosciences, Inc.: Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board | 297 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / April 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to... ► Artikel lesen | |
| 30.03. | Revelation Biosciences, Inc.: Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study | 153 | ACCESS Newswire | - A majority of CKD patients present with cellular inflammation and immunoparalysis predose --Gemini durably normalizes cellular inflammation and restores immunocompetence - SAN DIEGO, CA / ACCESS Newswire... ► Artikel lesen | |
| 24.03. | Revelation Biosciences, Inc.: REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference | 164 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| 19.03. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| REVELATION BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 19.03. | Revelation Biosciences, Inc.: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference | 312 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / March 19, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| 27.02. | Revelation Biosciences reports FY results | 2 | Seeking Alpha | ||
| 26.02. | Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025 | 365 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / February 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| 29.01. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | - | SEC Filings | ||
| 26.01. | Revelation Biosciences kündigt Reverse-Split im Verhältnis 1:4 an | 3 | Investing.com Deutsch | ||
| 26.01. | Revelation Biosciences to implement 1-for-4 reverse stock split | 3 | Investing.com | ||
| 26.01. | Revelation Biosciences, Inc.: Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026 | 713 | ACCESS Newswire | SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), announced today that, on January 28, 2026, the Company will implement... ► Artikel lesen | |
| 23.01. | Revelation Biosciences sichert sich Kapital durch Ausübungsvereinbarung für Optionsscheine | 3 | Investing.com Deutsch | ||
| 23.01. | Revelation Biosciences announces warrant exercise agreement | 1 | Investing.com | ||
| 23.01. | Revelation Biosciences, Inc.: Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds | 414 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / January 23, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| 23.01. | Why Did Revelation Biosciences (REVB) Stock Jump Over 25% After-Hours? | 11 | Benzinga.com | ||
| 22.01. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 21.01. | Revelation Biosciences, Inc.: Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI | 374 | ACCESS Newswire | - Single Phase 2/3 Adaptive Study Design -- Clinically Relevant, Objective Composite Endpoint - SAN DIEGO, CA / ACCESS Newswire / January 21, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company"... ► Artikel lesen | |
| 14.01. | Revelation Biosciences, Inc.: Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology | 365 | ACCESS Newswire | - Presentation to Include Additional Positive Data from the Recently Completed PRIME Clinical Study - SAN DIEGO, CA / ACCESS Newswire / January 14, 2026 / Revelation Biosciences Inc. (NASDAQ:REVB) (the... ► Artikel lesen |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 32,540 | -4,50 % | Aktien New York Ausblick: Moderate Gewinne - Lage in Nahost sorgt für Vorsicht | NEW YORK (dpa-AFX) - Am US-Aktienmarkt werden am Dienstag zum Handelsstart moderate Gewinne erwartet. Angesichts der unsicheren Lage in Nahost dominiert - wie bereits zum Wochenstart - die Vorsicht.... ► Artikel lesen | |
| ERASCA | 22,480 | 0,00 % | Erasca, Inc. - 8-K, Current Report | ||
| BIONTECH | 90,50 | -2,58 % | Jetzt einsteigen? BioNTech-Aktie mit Kaufsignal! | Nach dem Abgang der Gründer zeigen sich die BioNTech-Anteile inzwischen erholt. Am Donnerstag ist es sogar zu einem ersten Kaufsignal gekommen. Jetzt zugreifen? BioNTech wird von der starken Branche... ► Artikel lesen | |
| ARCELLX | 115,04 | +0,04 % | Gilead Sciences, Inc. Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer | FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that all required regulatory approvals have been obtained for its previously announced acquisition of Arcellx... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 22,260 | -9,40 % | Stifel reiterates Summit Therapeutics stock rating on trial data | ||
| EVOTEC | 5,400 | -5,01 % | Shortseller-Positionen aktuell: u.a. Auto1, Carl Zeiss Meditec, Evotec, Kontron, Puma, Renk, Verve, Zalando | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| ADMA BIOLOGICS | 11,075 | +1,23 % | Does ADMA Biologics' Growth Story Outweigh Short-Seller Concerns? | ||
| CG ONCOLOGY | 69,90 | +0,06 % | CG Oncology-Aktie erreicht Rekordhoch von 72,29 US-Dollar | ||
| NUVALENT | 108,07 | -0,75 % | Nuvalent präsentiert AACR-Daten vor PDUFA-Entscheid im September | ||
| INHIBRX BIOSCIENCES | 119,88 | +4,16 % | Morning Market Movers: Axe Compute, Inhibrx Biosciences, Huachen AI Parking Management Technology, 1-800-FLOWERS.COM See Big Swings | OTTAWA (dpa-AFX) - At 9:00 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,870 | 0,00 % | Stifel reiterates Tango Therapeutics stock rating on combo potential | ||
| BEAM THERAPEUTICS | 30,160 | -4,83 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| RELAY THERAPEUTICS | 15,080 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 | 400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast... ► Artikel lesen | |
| STRYKER | 281,80 | +0,11 % | Following Stryker Cyberattack, Avatier Launches Identity Challenge Card to Protect Organizations When Standard Security Fails | New Solution Delivers the First Auto-Enrolled, Air-Gapped Multi-Factor Authentication (MFA) That Can Be Deployed Enterprise-Wide in a Single Day: No Devices, Apps, or Network Connectivity RequiredPLEASANTON... ► Artikel lesen | |
| COGENT BIOSCIENCES | 36,130 | -0,77 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 |
REVELATION BIOSCIENCES INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,170 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVELATION BIOSCIENCES INC finden Sie auf Wallstreet Online.